Vytrus Biotech

Vytrus Biotech, listed on the BME Growth market (VYT) since 2022, operates as a specialized developer and producer of high-value active ingredients for the global dermo-cosmetic industry. The company was established in 2009 as a spin-off from the Faculty of Pharmacy at the University of Barcelona by co-founders Albert Jané and Òscar Expósito. Jané, with a background in biotechnology and pharmaceutical sciences, serves as President and co-CEO, while Expósito, who holds a PhD in Plant Biotechnology, acts as co-CEO and Chief Scientific Officer. Their combined expertise in plant science and business management has shaped the firm's direction. The company reached operational break-even in 2020, transitioning from a startup to a profitable industrial entity.

The core of Vytrus Biotech's business is its proprietary plant stem cell biofactory technology. This platform allows the company to cultivate plant cells in controlled laboratory conditions, which significantly reduces the consumption of soil and water by over 99% compared to traditional agricultural methods. This sustainable approach enables the development of potent, safe, and patentable ingredients from rare or protected plant species without impacting ecosystems. The business model is B2B, supplying these active ingredients to cosmetic manufacturers worldwide for use in skincare and haircare formulations. The company generates revenue through the sale of its product portfolio, which is distributed in more than 50 countries across Europe, the US, and Asia.

Vytrus offers a portfolio of over 20 active ingredients, addressing cosmetic concerns such as aging, skin rejuvenation, hydration, and environmental protection. Key product technologies include Phyto-Peptidic Fractions™, Plasma Rich in Cell Factors™, and Phyto-Cell Fusions™. Notable products include Kannabia Sense™, derived from Cannabis Sativa stem cells for well-being and anti-wrinkle effects, and Deobiome Noni™, a prebiotic biological deodorant from Morinda citrifolia stem cells. Another offering, Clarivine™, uses grapevine stem cells to mimic cellular fasting effects, promoting skin longevity. The company has secured multiple patents and has received numerous international awards for its product developments. Financially, Vytrus reported revenues of €5 million and a net profit of €1 million in 2024, demonstrating significant growth. The firm's strategic plan for 2024-2027 aims to achieve €12 million in sales by expanding its technology base through both internal development and acquisitions.

Keywords: plant stem cell technology, cosmetic active ingredients, biotechnology, skincare ingredients, haircare ingredients, sustainable cosmetics, dermo-cosmetics, B2B cosmetics supplier, natural actives, Òscar Expósito, Albert Jané, BME Growth, plant biofactories, cosmetic innovation, microbiota, anti-aging, sustainable ingredient production, cosmetic formulation, plant peptides, cellular oil, biological deodorant